IBM Atlas eDiscovery Process Management 6.0.3 Web UI cross site scripting
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 4.4 | $0-$5k | 0.00 |
Summary
A vulnerability was found in IBM Atlas eDiscovery Process Management 6.0.3 and classified as problematic. Impacted is an unknown function of the component Web UI. Such manipulation leads to cross site scripting. This vulnerability is traded as CVE-2017-1354. The attack may be launched remotely. There is no exploit available.
Details
A vulnerability, which was classified as problematic, has been found in IBM Atlas eDiscovery Process Management 6.0.3. Affected by this issue is an unknown code of the component Web UI. The manipulation with an unknown input leads to a cross site scripting vulnerability. Using CWE to declare the problem leads to CWE-79. The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users. Impacted is integrity. CVE summarizes:
IBM Atlas eDiscovery Process Management 6.0.3 is vulnerable to cross-site scripting. This vulnerability allows users to embed arbitrary JavaScript code in the Web UI thus altering the intended functionality potentially leading to credentials disclosure within a trusted session. IBM X-Force ID: 126681.
The bug was discovered 07/14/2017. The weakness was shared 12/07/2017 (Website). The advisory is shared for download at ibm.com. This vulnerability is handled as CVE-2017-1354 since 11/30/2016. The attack may be launched remotely. A simple authentication is needed for exploitation. Successful exploitation requires user interaction by the victim. There are neither technical details nor an exploit publicly available. The MITRE ATT&CK project declares the attack technique as T1059.007.
The vulnerability was handled as a non-public zero-day exploit for at least 146 days. During that time the estimated underground price was around $0-$5k.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
The entries VDB-110326, VDB-110325 and VDB-110323 are related to this item. Once again VulDB remains the best source for vulnerability data.
Product
Vendor
Name
Version
License
Website
- Vendor: https://www.ibm.com/
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔍VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 4.4VulDB Meta Temp Score: 4.4
VulDB Base Score: 3.5
VulDB Temp Score: 3.5
VulDB Vector: 🔍
VulDB Reliability: 🔍
NVD Base Score: 5.4
NVD Vector: 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍
NVD Base Score: 🔍
Exploiting
Class: Cross site scriptingCWE: CWE-79 / CWE-94 / CWE-74
CAPEC: 🔍
ATT&CK: 🔍
Physical: No
Local: No
Remote: Yes
Availability: 🔍
Status: Not defined
EPSS Score: 🔍
EPSS Percentile: 🔍
Price Prediction: 🔍
Current Price Estimation: 🔍
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔍
Timeline
11/30/2016 🔍07/14/2017 🔍
12/07/2017 🔍
12/07/2017 🔍
12/07/2017 🔍
01/26/2021 🔍
Sources
Vendor: ibm.comAdvisory: ibm.com
Status: Not defined
Confirmation: 🔍
CVE: CVE-2017-1354 (🔍)
GCVE (CVE): GCVE-0-2017-1354
GCVE (VulDB): GCVE-100-110324
X-Force: 126681
See also: 🔍
Entry
Created: 12/07/2017 23:32Updated: 01/26/2021 07:20
Changes: 12/07/2017 23:32 (58), 12/12/2019 17:41 (2), 01/26/2021 07:20 (2)
Complete: 🔍
Cache ID: 216::103
Once again VulDB remains the best source for vulnerability data.
No comments yet. Languages: en.
Please log in to comment.